Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

Inclusion Criteria:

• Age ≥ 50 years and ≤80;
• Active PCV confirmed by ICGA+FFA (Indocyanine green angiography + fundus fluorescein angiography);
• At least one distinguishable polyp was shown in ICGA;
• BCVA between 24 to 73 letters with ETDRS chart (Early Treatment of Diabetic Retinopathty Study);
• The greatest linear dimension of the lesion <5400μm.

Exclusion Criteria:

• Previously received treatment of laser retina photocoagulation, transpupillary thermotherapy, pneumatic displacement of subretinal blood or any investigational treatment;
• Previous photodynamic therapy or anti-Vegf treatment within 6 months in study eye
• Previously received treatment of photodynamic treatment within 1 month, or any anti-vascular endothelial growth factor (VEGF) intraocular injection in 3 months in the fellow eye;
• Combine of current vitreous hemorrhage or extensive subretinal hemorrhage (lesion area >30mm2);
• A history of angioid streaks, presumed ocular histoplasmosis syndrome or pathologic myopia;
• Experienced retinal pigmental epithelium (RPE) tear, retinal detachment, macular hole or uncontrolled glaucoma;
• Undergone intraocular surgery (except uncomplicated cataract extraction with intraocular lens implantation);
• Cataract extraction with intraocular lens implantation within 60 days;
• Combine of cataract that could require medical or surgical intervention during 12 months;
• Combine of diabetes mellitus and have poor glucose control (Haemoglobin A1c (HbA1c) >8%);
• Combine of hypertension and have poor blood pressure control (blood pressure ≥140/95 mmHg after regular antihypertensive drugs treatment);
• History of myocardial infarction or cerebral infarction in last 6 months;
• During gestation period or lactation period;
• Combine of confirmed systemic autoimmune disease or any uncontrollable clinical conditions (e.g. HIV, malignant tumor, active hepatitis, severe systemic disease, diseases need immediately surgical treatment).